Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
26 Août 2024 - 2:00PM
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that
the company will participate in the Morgan Stanley 22nd Annual
Global Healthcare Conference on Thursday, September 5, 2024 at
10:45 A.M. ET.
The presentation will be webcast live and may be accessed here
or by visiting Madrigal’s Investor Relations Events page. A replay
of the webcast will be available after the event.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company
pursuing novel therapeutics for nonalcoholic steatohepatitis
(NASH), a liver disease with high unmet medical need. Madrigal’s
medication, Rezdiffra (resmetirom), is a once-daily, oral,
liver-directed THR-β agonist designed to target key underlying
causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor ContactTina Ventura,
IR@madrigalpharma.com
Media ContactChristopher
Frates, media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
